Why Investors Should Love Celgene's Apremilast
May 14th 2013 5:53PM
Updated May 14th 2013 5:56PM
Celgene shareholders didn't have to wait long for good news in 2013. On Jan. 7, the company announced positive results for two phase 3 studies of apremilast in treating psoriasis. Is apremilast really that big of a deal for Celgene investors? You bet. Here's why.
All in the family
The clinical success of apremilast is yet another feather in the cap of Celgene's research and development. It also reflects a continuation of the company's long history with its granddaddy of drugs, Thalomid. While Thalomid certainly had its ups and downs over nearly 60 years, Celgene's research with analogs of the drug paid off tremendously with Revlimid, Pomalyst, and now apremilast.
Despite being in the same family tree as the other drugs, apremilast works quite differently. It also belongs to another family of drugs called phosphodiesterase type 4, or PDE4, inhibitors. These drugs block the enzyme PDE4, which breaks down cyclic adenosine monophosphate, or cAMP. The problem with this is that cAMP is important in extracellular signaling known as signal transduction. In a nutshell, too much of a breakdown in cAMP by these PDE4 enzymes means that the human body isn't a happy camper.
PDE4 inhibitors have shown potential for treating a variety of indications, including chronic obstructive pulmonary disease, asthma, depression, Alzheimer's disease, and Parkinson's disease. Celgene's focus with apremilast, though, has been on treating inflammatory conditions. Apremilast increases cAMP levels, which then reduces inflammatory responses in cells.
Why investors should love it
So, why should investors love apremilast? Let us count the ways.
Celgene's first New Drug Application, or NDA, for apremilast will be for psoriatic arthritis. The company expects to submit that NDA in the first quarter, followed by another for psoriasis in the second half of 2013. A combined Marketing Authorization Application, or MAA, for both indications will be submitted in Europe also in the second half of the year.
Psoriatic arthritis and psoriasis present a significant market potential. As many as 125 million people across the world have psoriasis, including up to 7.5 million Americans. Between 10% and 30% of those individuals also develop psoriatic arthritis.
Of course, this huge market already has several major drugs in the mix. AbbVie's Humira currently stands as the biggest player, followed by Enbrel from Amgen and Pfizer and two drugs from Johnson & Johnson : Remicade and Simponi. Can Celgene realistically expect to compete against these biologic juggernauts? I think it can.
One reason is that apremilast is administered orally rather than via injection as the other drugs are. Another is that the apremilast looks to be quite safer than the other drugs. While Celgene's drug doesn't appear to be quite as robust in treating psoriatic arthritis as the biologics, its convenience and safety profile should enable it to gain traction.
Celgene is counting on between $1.5 billion and $2 billion in sales for apremilast by 2017. Considering that Celgene's current revenue is $5.5 billion, apremilast's opportunities present plenty of reasons for investors to love this drug.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.
The article Why Investors Should Love Celgene's Apremilast originally appeared on Fool.com.Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.